Izba

Travoprost, the active ingredient in Izba, is a prostaglandin analog formulated as an ophthalmic solution for ocular administration. It is indicated for the reduction of elevated intraocular pressure in adults diagnosed with primary open-angle glaucoma or ocular hypertension, helping to preserve visual function.

GNH USA supplies Izba as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality standards. The product complies with European Union marketing authorisation requirements and is distributed under controlled conditions to ensure integrity throughout the supply chain.

Travoprost is a prostaglandin analog used to manage ocular hypertension and glaucoma by enhancing aqueous humor outflow.

Primary open-angle glaucoma: reduces intraocular pressure to slow disease progression. Ocular hypertension: lowers elevated eye pressure to prevent conversion to glaucoma. Secondary open-angle glaucoma: assists in lowering pressure when caused by other ocular conditions.

Common Side Effects: - Eye redness: transient hyperemia of the conjunctiva. - Eyelash changes: increased length or thickness of lashes. - Eye irritation: burning or stinging sensation after instillation. - Darkening of iris: gradual increase in brown pigmentation.

Serious or Rare Side Effects: - Macular edema: swelling of the central retina that may affect vision. - Anterior uveitis: inflammation of the front structures of the eye. - Severe allergic reaction: swelling, itching, or rash around the eye.

Before initiating therapy, consider the following precautions: - Monitor intraocular pressure: measure regularly after starting treatment. - Assess for ocular infections: avoid use if an active eye infection is present. - Avoid contact lens wear: discontinue lenses before and after instillation. - Use with caution in patients with cystoid macular edema. - Pregnancy and lactation: safety not established; weigh potential risks and benefits. - Store at room temperature: keep the bottle in its original packaging, protect from light and moisture.

Travoprost may interact with other ocular or systemic agents. Review the following interactions:

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may reduce Travoprost efficacy. - Systemic carbonic anhydrase inhibitors: additive intraocular pressure‑lowering effect, requiring pressure monitoring. - Beta‑blocker eye drops: combined use can cause excessive pressure reduction.

Moderate Interactions (Monitor Closely): - Other prostaglandin analogs: avoid simultaneous use due to overlapping mechanisms. - Topical corticosteroids: may diminish the intraocular pressure‑lowering effect of Travoprost.